Title: Circulating microRNAs as predictors of response to Sofosbuvir + Daclatasvir + Ribavirin
in in HCV genotype-4 Egyptian patients.
Version: 1 Date: 04 Jun 2022
Reviewer's report:
Dear Author
Thank you fro submitting this manuscript.
kindly find below my comments:
-I have a concern about the aim in this study, it is well known that response to DAA is already
more than 90% unlike IFN, so the search for markers of response could be narrowed to only those
who are difficult to treat patients. In view of this, do we need to study predictors of response??
As regards sections of the manuscript:
-Introduction is too long, needs to be summarized to the role of miRNA in repose to ttt
-Patients and Methods: you need to add sample size, regimen of DAA included reflects that all
patients had liver cirrhotic or were treatment experienced to DAA before, please add more data
to  your patients including non-responders.
Also i believe that you can classify patients into responders and non responders
-Discussion needs explanatation of your results
-In Figure 1; please refer that these results were taken baseline before ttt or otherwise?? and
actually u need to compare pre and post levels.
Title: Circulating microRNAs as predictors of response to Sofosbuvir + Daclatasvir + Ribavirin
in in HCV genotype-4 Egyptian patients.
Version: 1 Date: 04 Jun 2022
Reviewer's report:
Dear Author
Thank you fro submitting this manuscript.
kindly find below my comments:
-I have a concern about the aim in this study, it is well known that response to DAA is already
more than 90% unlike IFN, so the search for markers of response could be narrowed to only those
who are difficult to treat patients. In view of this, do we need to study predictors of response??
As regards sections of the manuscript:
-Introduction is too long, needs to be summarized to the role of miRNA in repose to ttt
-Patients and Methods: you need to add sample size, regimen of DAA included reflects that all
patients had liver cirrhotic or were treatment experienced to DAA before, please add more data
to  your patients including non-responders.
Also i believe that you can classify patients into responders and non responders
-Discussion needs explanatation of your results
-In Figure 1; please refer that these results were taken baseline before ttt or otherwise?? and
actually u need to compare pre and post levels.
Please review this paper.
user
Title: Circulating microRNAs as predictors of response to Sofosbuvir + Daclatasvir + Ribavirin
in in HCV genotype-4 Egyptian patients.
Version: 1 Date: 04 Jun 2022
Reviewer's report:
Dear Author
Thank you fro submitting this manuscript.
kindly find below my comments:
-I have a concern about the aim in this study, it is well known that response to DAA is already
more than 90% unlike IFN, so the search for markers of response could be narrowed to only those
who are difficult to treat patients. In view of this, do we need to study predictors of response??
As regards sections of the manuscript:
-Introduction is too long, needs to be summarized to the role of miRNA in repose to ttt
-Patients and Methods: you need to add sample size, regimen of DAA included reflects that all
patients had liver cirrhotic or were treatment experienced to DAA before, please add more data
to  your patients including non-responders.
Also i believe that you can classify patients into responders and non responders
-Discussion needs explanatation of your results
-In Figure 1; please refer that these results were taken baseline before ttt or otherwise?? and
actually u need to compare pre and post levels.
assistant